RXRX

Recursion Pharmaceuticals Inc

4.35

Oct 28 • 3:59 PM ET +0.30 (7.41%)

4.25

Aftermarket • 7:59 PM ET -0.10 (-2.30%)

Healthcare Biotechnology USA Mid NASD

Peers: ABSI GENB ABCL DNA RLAY EIKN HYFT TWST OABI LTRN

| Held by: ARKE ARKK XBI VTI ARKG IWM VB VBK VXF IWN

Scroll to Statements

Index	RUT
Market Cap	2.60B
Enterprise Value	2.12B
Income	-518.88M
Sales	54.85M
Book/sh	1.71
Cash/sh	0.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	600
IPO	Apr 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	47.41
P/B	2.54
P/C	4.72
P/FCF	-
EV/EBITDA	-
EV/Sales	38.58
Quick Ratio	5.03
Current Ratio	5.03
Debt/Eq	0.07
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-1.04
EPS next Y	-0.87
EPS next Q	-0.22
EPS this Y	37.51%
EPS next Y	3.00%
EPS next 5Y	20.14%
EPS past 3/5Y	-1.84% -22.39%
Sales past 3/5Y	23.30% 79.91%
EPS Y/Y TTM	41.98%
Sales Y/Y TTM	-15.08%
EPS Q/Q	40.28%
Sales Q/Q	-60.10%
Earnings	Nov 02 AMC
EPS/Sales Surpr.	-4.17% -33.42%

Insider Own	10.21%
Insider Trans	-0.67%
Inst Own	55.53%
Inst Trans	4.19%
ROA	-41.26%
ROE	-56.58%
ROIC	-54.11%
Gross Margin	-88.39%
Oper. Margin	-991.72%
Profit Margin	-945.92%
SMA20	9.05%
SMA50	17.05%
SMA200	23.11%
Trades

Shs Outstand	597.81M
Shs Float	536.80M
Short Float	30.17%
Short Ratio	7.45
Short Interest	161.93M
52W High	6.25 -30.40%
52W Low	2.77 57.04%
Volatility	8.19% 10.58%
ATR (14)	0.35
RSI (14)	59.14
Beta	1.15
Rel Volume	1.31
Avg Volume	21.74M
Volume	28,497,128

Perf Week	19.51%
Perf Month	7.94%
Perf Quarter	43.09%
Perf Half Y	31.82%
Perf YTD	6.36%
Perf Year	-26.40%
Perf 3Y	-17.61%
Perf 5Y	-77.53%
Perf 10Y	-
Recom	2.14
Target Price	7.32
Prev Close	4.05
Price	4.35
Change %	7.41%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight	$11
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$5
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Oct-26-26 11:36PM	Recursion's Clinical Push Faces Test As Stock Rally Meets Leadership Questions And Lumpy Revenue (Earnings Whispers) +6.58%
04:05PM	Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 (GlobeNewswire)
Oct-16-26 12:10PM	Iambic CEO on taking an AI drug company public (BioPharma Dive) -16.71%
Oct-15-26 01:59PM	RXRX Stock Heads For Its Best Day In Over A Year Whats Driving The Rally Today? (Stocktwits) +11.23%
08:45AM	Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration (GlobeNewswire)
08:30AM	Loading…
08:30AM	Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock (GlobeNewswire)
08:22AM	Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone (GlobeNewswire)
Oct-13-26 09:23AM	FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation (Investing.com)
Oct-08-26 07:58PM	What Could Go Wrong With Recursion Pharmaceuticals Stock? (Trefis) -7.49% +10.38%
Oct-06-26 12:30PM	Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial (FinanceWire)
08:16AM	Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies Unloads $18M Worth Of TWST Shares (Stocktwits)
Sep-23-26 03:31PM	Enveda secures $311M to bring more nature-derived AI drugs into clinical trials (TechCrunch) -8.64%
Sep-21-26 09:14AM	Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursions RNA Foundation Model (Business Wire)
Aug-12-26 03:30PM	These Are the Stocks Wall Street Is Betting Against the Most (GuruFocus.com)
Aug-05-26 06:41AM	Recursion Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
06:30AM	Loading…
06:30AM	Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program (GlobeNewswire)
Aug-04-26 09:39AM	Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q2 2026 -- GF Value Sees 43% Upside (GuruFocus.com)
08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-26 04:30PM	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire) +6.00%
Jul-29-26 08:30AM	Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th (GlobeNewswire)
Jul-24-26 09:10AM	A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed (PR Newswire)
Jul-01-26 09:04AM	Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX (GuruFocus.com)
09:00AM	As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data (PR Newswire)
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
Jun-16-26 08:45AM	The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It (PR Newswire)
Jun-15-26 02:48PM	Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD (GuruFocus.com)
Jun-02-26 08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-29-26 04:30PM	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire) +5.57%
May-27-26 10:43AM	Verge, following trial failure, rebrands its AI drug discovery ambitions (BioPharma Dive) +6.73%
May-06-26 06:36AM	Recursion Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
06:30AM	Loading…
06:30AM	Recursion Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-26 04:30PM	Recursion Announces Board Transition (GlobeNewswire)
Apr-29-26 07:59AM	Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 (GlobeNewswire)
Apr-21-26 06:37AM	The top 10 most shorted stocks in the U.S. (MarketWatch)
Apr-07-26 08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-26 07:59AM	Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer (GlobeNewswire)
Mar-10-26 05:45PM	Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Mar-09-26 08:11PM	What Makes Recursion Pharmaceuticals (RXRX) So Attractive (Insider Monkey)
Mar-06-26 12:01PM	BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating (Insider Monkey)
Feb-27-26 09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:37AM	Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Feb-26-26 08:00PM	Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Call Highlights: Strategic Milestones and ... (GuruFocus.com)
02:27PM	Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M (Insider Monkey)
10:08AM	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
Feb-25-26 05:25PM	Recursion Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) +6.80%
12:15PM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
10:54AM	What's Behind The Jump In Recursion Pharmaceuticals Stock? (Benzinga)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
06:38AM	Recursion Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 03:52PM	ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025 (Benzinga)
07:25AM	Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-23-26 02:47PM	Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts (Insider Monkey)
10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks)
08:00AM	Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC (GlobeNewswire)
07:55AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-26 05:45PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks) -8.06%
10:01AM	Cathie Wood Pours $24 Million to This AI Software Stock (GuruFocus.com)
Feb-19-26 05:10PM	Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates (Zacks) +5.38%
04:47PM	Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? (Barchart)
11:14AM	NVIDIAs 13F Bombshell: A New AI Power Trio Emerges (MarketBeat)
05:27AM	Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. (Barrons.com)
Feb-18-26 05:50PM	Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider (Zacks)
04:40PM	Applied Digital, WeRide Stocks Drop. Blame Nvidia. (Barrons.com)
02:07PM	Recursion Pharmaceuticals Stock Drops: What's Behind It? (Benzinga)
01:21PM	Nvidia Sold Its Stakes in These Firms. The Stocks Are Sliding. (Investopedia)
09:37AM	Applied Digital, WeRide Stocks Drop After Nvidia Sells Holdings (The Wall Street Journal)
08:30AM	Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 (GlobeNewswire)
05:43AM	Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. (Barrons.com)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-12-26 10:00AM	2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off (24/7 Wall St.)
07:59AM	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire)
Feb-10-26 05:45PM	Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Feb-04-26 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -8.72%
Jan-29-26 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
06:15AM	Forget 2025: These 2 Growth Stocks Could Soar in 2026 (Motley Fool)
Jan-28-26 09:21PM	Can This Beaten-Down AI Stock Bounce Back in 2026? (Motley Fool)
Jan-24-26 03:35AM	Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? (Insider Monkey)
Jan-23-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-20-26 10:14AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) -5.78%
Jan-18-26 12:30PM	JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects (Insider Monkey)
Jan-16-26 05:05PM	2 AI Stocks to Buy in 2026, and 1 to Avoid (Motley Fool) -5.78%
Jan-15-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-08-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-07-26 08:20PM	Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates (Insider Monkey) +6.81%
Jan-06-26 07:59AM	Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
09:10AM	JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline (Insider Monkey)
Jan-01-26 07:45AM	Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. (Motley Fool)
Dec-30-25 11:49PM	Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) (Insider Monkey)
Dec-29-25 11:42AM	Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP (Insider Monkey)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Dec-28-25 12:46PM	Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform (Insider Monkey)
Dec-24-25 09:00AM	Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? (Barchart)
Dec-21-25 07:40AM	Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? (Insider Monkey)
Dec-19-25 07:33AM	Cathie Wood Keeps Dumping Tesla Stock -- Here is Why (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Borgeson Blake	Director	Oct 06 '26	Sale	4.84	50,000	242,000	6,108,287	Oct 07 06:08 PM
HERSHBERG ROBERT	Director	Oct 06 '26	Option Exercise	2.22	25,000	55,500	187,156	Oct 07 06:08 PM
HERSHBERG ROBERT	Director	Oct 06 '26	Sale	5.00	25,000	125,000	162,156	Oct 07 06:08 PM
Borgeson Blake	Director	Oct 06 '26	Proposed Sale	4.84	50,000	242,000		Oct 06 11:48 AM
HERSHBERG ROBERT	Director	Oct 06 '26	Proposed Sale	5.00	25,000	125,000		Oct 06 11:09 AM
Khan Najat	CEO and President	Sep 08 '26	Sale	3.52	22,408	78,822	2,072,890	Sep 10 05:55 PM
Najat Khan	Officer	Sep 08 '26	Proposed Sale	3.52	22,408	78,822		Sep 08 02:28 PM
Borgeson Blake	Director	Sep 01 '26	Sale	3.34	30,000	100,200	6,158,287	Sep 02 06:01 PM
Borgeson Blake	Director	Sep 01 '26	Proposed Sale	3.34	30,000	100,200		Sep 01 04:21 PM
Gibson Christopher	Former Director	Aug 21 '26	Proposed Sale	3.39	77,290	262,013		Aug 21 11:27 AM
Gibson Christopher	Former Director	Aug 20 '26	Proposed Sale	3.40	75,000	255,000		Aug 20 11:32 AM
Gibson Christopher	Former Director	Aug 19 '26	Proposed Sale	3.27	100,000	327,500		Aug 19 11:54 AM
Gibson Christopher	Former Director	Aug 18 '26	Proposed Sale	3.00	26,806	80,399		Aug 18 05:14 PM
Gibson Christopher	Former Director	Aug 13 '26	Proposed Sale	3.31	100,000	331,000		Aug 13 12:58 PM
Gibson Christopher	Former Director	Aug 12 '26	Proposed Sale	3.37	50,000	168,500		Aug 12 11:56 AM
Gibson Christopher	Former Director	Aug 10 '26	Proposed Sale	3.27	100,000	326,754		Aug 10 04:59 PM
Gibson Christopher	Former Director	Aug 07 '26	Proposed Sale	3.25	100,000	325,410		Aug 07 12:42 PM
Borgeson Blake	Director	Aug 04 '26	Sale	3.25	30,000	97,500	6,188,287	Aug 06 05:09 PM
Borgeson Blake	Director	Aug 04 '26	Proposed Sale	3.25	30,000	97,500		Aug 04 01:37 PM
Gibson Christopher	Former Director	Aug 04 '26	Proposed Sale	3.27	75,000	244,875		Aug 04 10:35 AM
Gibson Christopher	Former Director	Jul 30 '26	Proposed Sale	3.00	75,000	225,000		Jul 30 04:10 PM
Gibson Christopher	Former Director	Jul 29 '26	Proposed Sale	3.03	50,000	151,372		Jul 29 04:09 PM
Gibson Christopher	Former Director	Jul 27 '26	Proposed Sale	3.05	50,000	152,703		Jul 27 04:16 PM
Gibson Christopher	Former Director	Jul 21 '26	Proposed Sale	3.04	100,000	304,263		Jul 21 04:11 PM
Gibson Christopher	Former Director	Jul 20 '26	Proposed Sale	2.90	100,000	289,766		Jul 20 04:11 PM
Gibson Christopher	Former Director	Jul 17 '26	Proposed Sale	2.97	100,000	296,726		Jul 17 04:10 PM
Gibson Christopher	Former Director	Jul 16 '26	Proposed Sale	3.11	100,000	311,065		Jul 16 04:13 PM
Gibson Christopher	Former Director	Jul 15 '26	Proposed Sale	3.33	123,334	410,283		Jul 15 04:12 PM
Gibson Christopher	Former Director	Jul 14 '26	Proposed Sale	3.30	100,000	330,473		Jul 14 04:07 PM
Gibson Christopher	Former Director	Jul 13 '26	Proposed Sale	3.43	100,000	343,048		Jul 13 04:32 PM
Gibson Christopher	Former Director	Jul 10 '26	Proposed Sale	3.54	100,000	353,577		Jul 10 04:09 PM
Borgeson Blake	Director	Jul 07 '26	Sale	3.96	40,000	158,500	6,218,287	Jul 09 06:04 PM
Gibson Christopher	Former Director	Jul 09 '26	Proposed Sale	3.80	286,000	1,085,716		Jul 09 04:26 PM
Gibson Christopher	Former Director	Jul 08 '26	Proposed Sale	3.69	200,000	737,694		Jul 08 04:26 PM
Gibson Christopher	Former Director	Jul 07 '26	Proposed Sale	3.95	250,000	987,500		Jul 07 01:39 PM
Borgeson Blake	Director	Jul 07 '26	Proposed Sale	3.96	40,000	158,500		Jul 07 11:36 AM
Gibson Christopher	Former Director	Jul 06 '26	Proposed Sale	3.78	100,000	378,000		Jul 06 03:28 PM
Gibson Christopher	Former Director	Jul 02 '26	Proposed Sale	3.75	100,000	374,500		Jul 02 12:54 PM
Gibson Christopher	Former Director	Jul 01 '26	Proposed Sale	3.67	100,000	366,630		Jul 01 05:19 PM
Bumpus Namandje	Director	Jun 18 '26	Sale	3.18	3,963	12,602	127,632	Jun 22 04:32 PM
Gibson Christopher	Director	Jun 18 '26	Proposed Sale	3.20	300,440	962,341		Jun 18 04:33 PM
Bumpus Namandje	Director	Jun 18 '26	Proposed Sale	3.18	3,963	12,602		Jun 18 09:44 AM
Gibson Christopher	Director	Jun 18 '26	Proposed Sale	3.18	40,000	127,200		Jun 18 09:37 AM
Gibson Christopher	Director	Jun 05 '26	Sale	3.62	40,000	144,800	883,735	Jun 05 05:03 PM
Khan Najat	CEO and President	Jun 05 '26	Sale	3.58	23,588	84,459	2,175,796	Jun 05 05:02 PM
Najat Khan	Officer	Jun 05 '26	Proposed Sale	3.58	23,588	84,459		Jun 05 01:29 PM
Gibson Christopher	Director	Jun 05 '26	Proposed Sale	3.62	40,000	144,800		Jun 05 10:19 AM
Bumpus Namandje	Director	Jun 03 '26	Sale	3.54	4,386	15,526	43,171	Jun 04 05:04 PM
Borgeson Blake	Director	Jun 02 '26	Sale	3.68	30,000	110,400	6,169,863	Jun 04 05:04 PM
Bumpus Namandje	Director	Jun 03 '26	Proposed Sale	3.54	4,386	15,526		Jun 03 10:16 AM
Borgeson Blake	Director	Jun 02 '26	Proposed Sale	3.68	30,000	110,400		Jun 02 11:04 AM
Gibson Christopher	Director	May 22 '26	Sale	3.08	40,000	123,200	883,735	May 27 04:15 PM
Gibson Christopher	Director	May 22 '26	Proposed Sale	3.08	40,000	123,200		May 22 10:13 AM
Gibson Christopher	Director	May 07 '26	Sale	3.37	40,000	134,800	926,556	May 08 04:59 PM
Borgeson Blake	Director	May 05 '26	Sale	3.52	30,000	105,600	6,199,863	May 07 04:44 PM
Gibson Christopher	Director	May 07 '26	Proposed Sale	3.37	40,000	134,800		May 07 11:13 AM
Borgeson Blake	Director	May 05 '26	Proposed Sale	3.52	30,000	105,600		May 05 10:22 AM
Gibson Christopher	Director	Apr 22 '26	Sale	3.61	40,000	144,400	906,556	Apr 24 04:23 PM
Gibson Christopher	Director	Apr 22 '26	Proposed Sale	3.61	40,000	144,400		Apr 22 09:47 AM
Gibson Christopher	Director	Apr 07 '26	Sale	3.10	40,000	124,000	906,556	Apr 08 04:58 PM
Borgeson Blake	Director	Apr 07 '26	Sale	3.10	30,000	93,000	6,229,863	Apr 08 04:58 PM
Gibson Christopher	Director	Apr 07 '26	Proposed Sale	3.10	40,000	124,000		Apr 07 10:46 AM
Borgeson Blake	Director	Apr 07 '26	Proposed Sale	3.10	30,000	93,000		Apr 07 10:17 AM
Gibson Christopher	Director	Mar 23 '26	Sale	3.25	40,000	130,000	906,556	Mar 25 04:36 PM
Gibson Christopher	Director	Mar 23 '26	Proposed Sale	3.25	40,000	130,000		Mar 23 10:49 AM
Taylor Ben R	Chief Financial Officer	Mar 17 '26	Sale	3.39	7,956	26,971	1,180,318	Mar 18 05:52 PM
Taylor Ben R	Officer	Mar 17 '26	Proposed Sale	3.39	7,956	26,971		Mar 17 10:53 AM
Khan Najat	CEO and President	Mar 09 '26	Sale	3.35	28,298	94,660	2,262,085	Mar 11 05:41 PM
Najat Khan	Officer	Mar 09 '26	Proposed Sale	3.35	28,298	94,662		Mar 09 01:45 PM
Borgeson Blake	Director	Mar 03 '26	Sale	3.46	170,000	588,200	6,259,863	Mar 04 04:38 PM
Borgeson Blake	Director	Mar 03 '26	Proposed Sale	3.46	170,000	588,200		Mar 03 12:45 PM
Gibson Christopher	Director	Feb 19 '26	Sale	3.46	40,000	138,400	906,556	Feb 19 07:30 PM
Taylor Ben R	Chief Financial Officer	Feb 18 '26	Sale	3.08	13,426	41,352	1,195,349	Feb 19 07:30 PM
Gibson Christopher	Director	Feb 19 '26	Proposed Sale	3.46	40,000	138,400		Feb 19 10:27 AM
Taylor Ben R	Officer	Feb 18 '26	Proposed Sale	3.08	13,426	41,352		Feb 18 12:21 PM
Gibson Christopher	Director	Feb 04 '26	Sale	4.12	40,000	164,800	913,839	Feb 06 05:53 PM
Borgeson Blake	Director	Feb 03 '26	Sale	4.20	220,000	924,000	6,429,863	Feb 06 05:53 PM
Gibson Christopher	Director	Feb 04 '26	Proposed Sale	4.12	40,000	164,800		Feb 04 09:50 AM
Borgeson Blake	Director	Feb 03 '26	Proposed Sale	4.20	220,000	924,000		Feb 03 11:26 AM
Gibson Christopher	Director	Jan 20 '26	Sale	4.47	40,000	178,800	913,839	Jan 22 07:34 PM
Gibson Christopher	Director	Jan 20 '26	Proposed Sale	4.47	40,000	178,800		Jan 20 11:26 AM
Borgeson Blake	Director	Jan 06 '26	Sale	4.36	220,000	959,200	6,649,863	Jan 08 05:01 PM
Gibson Christopher	Director	Jan 05 '26	Sale	4.25	40,000	170,000	933,839	Jan 07 05:04 PM
Borgeson Blake	Director	Jan 06 '26	Proposed Sale	4.36	220,000	959,200		Jan 06 09:40 AM
Gibson Christopher	Director	Jan 05 '26	Proposed Sale	4.25	40,000	170,000		Jan 05 11:07 AM
Taylor Ben R	Chief Financial Officer	Dec 29 '25	Sale	4.18	21,383	89,381	761,550	Dec 30 07:35 PM
Khan Najat	Chief R&D Commercial Officer	Dec 22 '25	Sale	4.41	124,403	548,592	611,135	Dec 29 05:24 PM
Taylor Ben R	Officer	Dec 29 '25	Proposed Sale	4.18	21,383	89,381		Dec 29 09:41 AM
Najat Khan	Officer	Dec 22 '25	Proposed Sale	4.41	124,403	548,588		Dec 22 12:20 PM
Gibson Christopher	Chief Executive Officer	Dec 19 '25	Sale	4.50	40,000	180,000	913,839	Dec 19 05:04 PM
Gibson Christopher	Officer	Dec 19 '25	Proposed Sale	4.50	40,000	180,000		Dec 19 09:52 AM
Gibson Christopher	Chief Executive Officer	Dec 04 '25	Sale	4.63	40,000	185,200	933,839	Dec 05 07:20 PM
Borgeson Blake	Director	Dec 02 '25	Sale	4.37	220,000	961,400	6,869,863	Dec 04 04:51 PM
Gibson Christopher	Officer	Dec 04 '25	Proposed Sale	4.63	40,000	185,200		Dec 04 10:01 AM
Borgeson Blake	Director	Dec 02 '25	Proposed Sale	4.37	220,000	961,400		Dec 02 12:15 PM
Gibson Christopher	Chief Executive Officer	Nov 19 '25	Sale	4.16	40,000	166,400	913,839	Nov 19 07:37 PM
Gibson Christopher	Officer	Nov 19 '25	Proposed Sale	4.16	40,000	166,400		Nov 19 10:17 AM
Gibson Christopher	Chief Executive Officer	Nov 04 '25	Sale	5.21	40,000	208,400	974,229	Nov 06 04:23 PM
Gibson Christopher	Officer	Nov 04 '25	Proposed Sale	5.21	40,000	208,400		Nov 04 09:51 AM

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

CEODr. Najat Khan Ph.D.

CFO & President of Recursion UKMr. Ben R. Taylor

Chief Technology OfficerMr. Benjamin Mabey M.S.

Chief Scientific OfficerDr. David Hallett Ph.D.

M.B.A.Mr. Nathan Hatfield J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RXRX

Recursion Pharmaceuticals Inc

Upgrade your Finviz experience